Pharmaceutical industry: Vaccines, traditional and emerging biological immune agents

Investment points: vaccines-an immune agent with preventive and therapeutic effects. Vaccines are automatic immunization preparations for the prevention of infectious diseases by means of artificial attenuated, inactivated or genetically engineered pathogens (such as bacteria, rickettsia, viruses, etc.) and their metabolites. The 1990s is known as the "new vaccine decade", especially in recent years with the development of molecular biology, immunology and other disciplines, in the field of medical research, many new vaccines continue to emerge.　　Vaccines are not only used for the prevention of infectious diseases, but also as a new treatment for various diseases such as hepatitis B, cancer, AIDS and Alzheimer's disease and multiple sclerosis. The global market-preventive vaccines, the future development of therapeutic vaccines larger space. According to Kalorama Information company, the global vaccine market has grown by more than 10 times times in the more than 20 years since 1980, while drug sales have grown only 5 times times in the same period, seeing that the global vaccine market is growing much faster than the market for drug sales in the 2007 global vaccine market has more than $10 billion trillion, One of the preventive vaccine accounted for up to 95%, while the therapeutic vaccine is less than 500 million U.S. dollars, industrial development is still in its infancy, the current global therapeutic vaccine listed varieties mainly cancer vaccine, the 2005 cancer vaccine market sales of 15.9 million U.S. dollars, 2006 breakthrough 100 million dollars,　　2007 480 million U.S. dollars, an average annual growth rate of more than 14 times times, is expected by 2012, the U.S. FDA will be through 8-10 new vaccines (blockbuster), which would make the total cancer vaccine sales of more than 8 billion U.S. dollars, the next 5 years annual growth rate of nearly 300%. China's market-the Chinese monopoly planned vaccine market, the treatment of hepatitis B vaccine expected breakthrough. At present, our country can produce 26 kinds of viruses and 41 kinds of vaccines, with an annual output of more than 1 billion dose units. The 2008-year planned vaccine market size is estimated at 152 billion yuan, the China Health group has almost monopolized the entire planned vaccine market, its subordinate six major production of vaccines accounted for more than 90% of the planned vaccine market, in recent years, there are a small number of private biological products enterprises and foreign companies actively involved in the planned vaccine bidding But the share of the new vaccine in China in the newly developed infectious diseases such as SARS, HIV and therapeutic hepatitis B vaccine research on the basic and international level, but in the cancer vaccine, subunit vaccine, and the combination of vaccine research and development in a relatively backward position. The treatment of hepatitis B vaccine has a number of listed companies in the development work, such as Chongqing Beer, the Temple of Heaven Biology and Guangzhou pharmaceutical industry; In addition, the National Drug Administration in 2004 approved China's Independent development of AIDS vaccine, and Ⅱ period of clinical research in Nanning, Guangxi, March 21, 2009 announced the official launch, This involves Changchun high-tech subsidiary Changchun Hundred Grams Pharmaceutical Co., Ltd. Plus Yueyang Hing eldest son company Chongqing Kang Wei on April 23, 2009 successfully developed the world's first stomach vaccine and passed three clinical trials, indicating that China is currently in the key new vaccine has been a breakthrough, and AIDSThe development of vaccines and therapeutic hepatitis B vaccines is also progressing steadily. We are optimistic about the future of new vaccines in the next few years.